Remarkable Response of Recurrent Endometrial Adenocarcinoma to Daily Oral Administration of Half-Dose Etoposide

SAGE Open Medical Case Reports
doi 10.1177/2050313x18819599
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Intracavitary Chemotherapy (Gliadel®) and Oral Low-Dose Etoposide for Recurrent Anaplastic Ependymoma

Oncology Reports
MedicineCancer ResearchOncology
2008English

Remarkable Response in a Case of Recurrent Gastrointestinal Stromal Tumor Treated With Low Dose Imatinib

Journal of Nihon University Medical Association
2016English

Remarkable Regression of Massive Deep Vein Thrombosis in Response to Intensive Oral Rivaroxaban Treatment

Thrombosis Journal
Hematology
2015English

Prevention of Recurrent Endometrial Pathology

Medical Council
2019English

Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System

International Journal of Medical Sciences
Medicine
2013English

Inhibition of Tumor Angiogenesis by Oral Etoposide

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2010English

Response to Daily

Journal of Medical Ethics
ArtsHumanitiesLegal AspectsHealth PolicyHealthEthicsIssues
1996English

Examination on Initial Dose in Introduction of Amiodarone Oral Administration. Trial of Initial Dose 800mg/Day.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1999English

An Exceptionally Favorable Response to Etoposide and Cisplatin

Cureus
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy